Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

US Food and Drug Administration

FDA calls for label change on anti-diarrhoea drug to stem misuse by opioid users

The US Food and Drug Administration (FDA) has called for sponsors of over-the-counter (OTC) anti-diarrhoea drug, loperamide, to change the way they label and package the drug to stem concerning misuse of the drug.

In a statement FDA commissioner Scott Gottlieb said loperamide misuse had been increasing in the United States with users attempting to achieve the euphoric effects of opioids and seeing it as a potential alternative to manage opioid withdrawal symptoms.

The maximum approved daily dose of loperamide, which is also sold as Imodium, for adults is 8mg per day for OTC use and 16mg per day for prescription use.

“Loperamide is safe at these approved doses. But when higher than recommended doses are taken we’ve received reports of serious heart problems and deaths with loperamide, particularly among people who are intentionally misusing or abusing high doses,” said Gottlieb.

The commissioner said the abuse of loperamide required the purchase of “extremely large quantities”, often achieved through buying large bottles of loperamide — a common form of packaging for the drug in pill form.

Therefore, the FDA is requesting that packages contain a limited amount of loperamide appropriate for use for short-term diarrhoea according to the product label.

Gottlieb said the FDA also plans to contact those who distribute loperamide online, through retail websites, to ask them to take voluntary steps to help address this abuse issue.

“I believe anyone who is distributing healthcare products has an obligation to be a partner in helping address the most pressing public health challenges such as opioid abuse,” he added.

In October 2017, the Medicines Healthcare products Regulatory Agency (MHRA) warned of serious cardiac adverse reactions in patients misusing or abusing loperamide by taking high or very high doses of the drug. It said that pharmacists should remind patients not to take more than the recommended dose on the label, and should report all suspected adverse reactions, including those associated with abuse or misuse, to the Yellow Card Scheme.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204338

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Imodium-loperamide-blister-pack-short-term-use

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.